Castleark Management LLC Sage Therapeutics, Inc. Transaction History

Castleark Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $646,634 - $1.66 Million	-10,745 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$140.29 - $189.96 $470,672 - $637,315	3,355 Added 45.4%	10,745 $1.51 Million
Q2 2019 Aug 13, 2019	BUY	$157.85 - $183.09 $1.17 Million - $1.35 Million	7,390 New	7,390 $1.35 Million
Q3 2018 Nov 15, 2018	SELL	$138.11 - $169.04 $3.17 Million - $3.88 Million	-22,950 Closed	0 $0
Q2 2018 Aug 15, 2018	SELL	$140.36 - $175.76 $17,685 - $22,145	-126 Reduced 0.55%	22,950 $3.59 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $824,500 - $1.04 Million	-5,419 Reduced 19.02%	23,076 $3.72 Million
Q4 2017 Feb 15, 2018	BUY	$60.72 - $167.34 $1.73 Million - $4.77 Million	28,495	28,495 $4.69 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $284M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.